Theravance Biopharma, Inc. Contracts & Agreements

Offer Letter with Brett Grimaud dated May 12, 2014 (Filed With SEC on May 10, 2023)

Offer Letter with Aziz Sawaf dated June 16, 2014 (Filed With SEC on May 10, 2023)

Form of Theravance Biopharma, Inc. 2013 Equity Incentive Plan Notice of Restricted Share Unit Award and Restricted Share Unit Agreement (Filed With SEC on May 10, 2023)

Amended and Restated 2013 Equity Incentive Plan of Theravance Biopharma, Inc (Filed With SEC on May 3, 2023)

Audited financial statements of Theravance Respiratory Company, LLC for the year ended December 31, 2021 (Filed With SEC on March 1, 2023)

Settlement Agreement and Release of Claims by and between Andrew Hindman and Theravance Biopharma US, Inc., dated January 10, 2023 (Filed With SEC on March 1, 2023)

First Amendment to the Theravance Biopharma, Inc. Change in Control Severance Plan (Filed With SEC on November 9, 2022)

Equity Purchase and Funding Agreement, dated as of July 13, 2022, by and between Theravance Biopharma, Inc. and Royalty Pharma Investments 2019 ICAV (Filed With SEC on July 14, 2022)

Master Consent, dated as of July 13, 2022, by and among Glaxo Group Limited, Theravance Biopharma, Inc. and Royalty Pharma Investments 2019 ICAV (Filed With SEC on July 14, 2022)

Release Agreement, dated as of July 13, 2022, by and among Innoviva, Inc., Innoviva TRC Holdings LLC, Royalty Pharma Investments 2019 ICAV, Theravance Respiratory Company, LLC,... (Filed With SEC on July 14, 2022)

Form of Separation Agreement and Release of Claims between California-based departing executives and Theravance Biopharma US, Inc (Filed With SEC on February 28, 2022)

Consulting Agreement between Vijay Sabesan and Theravance Biopharma US, Inc., dated November 30, 2021 (Filed With SEC on February 28, 2022)

Settlement Agreement by and between Ann Brady and Theravance Biopharma Ireland Limited, dated November 2, 2021 (Filed With SEC on February 28, 2022)

Audited financial statements of Theravance Respiratory Company, LLC for the year ended December 31, 2021 (Filed With SEC on February 28, 2022)

Underwriting Agreement among Theravance Biopharma, SVB Leerink LLC, Evercore Group L.L.C. and Credit Suisse Securities (USA) LLC, as representatives of the several underwriters,... (Filed With SEC on June 28, 2021)

Development and Commercialization Agreement by and between Theravance Biopharma R&D, Inc. and Mylan Ireland Limited, dated January 30, 2015 (Filed With SEC on February 26, 2021)

License and Collaboration Agreement by and between Theravance Biopharma Ireland Limited and Janssen Biotech, Inc. dated as of February 5, 2018 (Filed With SEC on February 26, 2021)

Offer Letter with Richard Graham August 12, 2015 (Filed With SEC on November 9, 2020)

Registration Rights Agreement among Theravance Biopharma, Inc., GSK Finance (No.3) plc and GlaxoSmithKline plc dated June 22, 2020 (Filed With SEC on June 25, 2020)

Waiver and Assignment of Registration Rights and Voting Agreement among GSK Finance (No.3) plc, Glaxo Group Limited and Theravance Biopharma, Inc. dated as of June 22, 2020 (Filed With SEC on June 25, 2020)

Cooperation Agreement among Theravance Biopharma, Inc., GSK Finance (No.3) plc and GlaxoSmithKline plc dated June 22, 2020 (Filed With SEC on June 25, 2020)

Brett K. Haumann Transfer to Theravance Biopharma UK Ltd. Memo (Filed With SEC on May 8, 2020)

Brett K. Haumann Theravance Biopharma UK Ltd. Contract of Employment (Filed With SEC on May 8, 2020)

First Amendment of Registration Rights Agreement with Glaxo Group Limited (Filed With SEC on May 8, 2020)

Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 27, 2020)

Form of Note Purchase Agreement, dated February 21, 2020 by and among Theravance Biopharma R&D, Inc., Triple Royalty Sub II LLC, and the Purchasers (Filed With SEC on February 27, 2020)

License Agreement by and between Theravance Biopharma Ireland Limited and Pfizer Inc. dated December 21, 2019 (Filed With SEC on February 27, 2020)

Underwriting Agreement among Theravance Biopharma, Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC and Cowen and Company, LLC, as representatives of the several underwriters,... (Filed With SEC on February 13, 2020)

Offer Letter with Andrew Hindman dated May 30, 2019 (Filed With SEC on August 5, 2019)

Amendment No. 1 to the Development and Commercialization Agreement by and between Theravance Biopharma Ireland Limited and Mylan Ireland Limited, dated June 12, 2019 (Filed With SEC on August 5, 2019)

Agreement and General Release between Theravance Biopharma US, Inc. and Shehnaaz Suliman, dated March 1, 2019 (Filed With SEC on May 10, 2019)

Form of Note Purchase Agreement, dated November 30, 2018 (Filed With SEC on December 3, 2018)

Asset Purchase Agreement, dated as of November 1, 2018, by and among Cumberland Pharmaceuticals Inc. on the one hand, and Theravance Biopharma Ireland Limited and Theravance... (Filed With SEC on November 16, 2018)

Memorandum to Brett K. Haumann regarding Transfer to Theravance Biopharma US, Inc., executed April 5, 2018 (Filed With SEC on August 2, 2018)

Amendments to Lease for 901 Gateway Boulevard between Theravance Biopharma US, Inc. and ARE-901/951 Gateway Boulevard, LLC (Filed With SEC on August 2, 2018)

Amendments to Lease for 951 Gateway Boulevard between Theravance Biopharma US, Inc. and ARE-901/951 Gateway Boulevard, LLC (Filed With SEC on August 2, 2018)

Amendment and Termination of Rights Agreement, dated as of May 1, 2018, between the Company and Computershare Inc (Filed With SEC on May 1, 2018)

Offer Letter with Shehnaaz Suliman dated May 31, 2017 (Filed With SEC on November 8, 2017)

Form of Notice of Option Grant and Option Agreement under the Companys Performance Incentive Plan (Filed With SEC on November 8, 2017)

Form of Notice of Performance Restricted Share Unit Award and Restricted Share Unit Agreement under the Companys Performance Incentive Plan (Filed With SEC on November 8, 2017)

FIRST AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT BETWEEN HOSPIRA WORLDWIDE, INC. and THERAVANCE, INC. (Filed With SEC on November 9, 2016)

SECOND AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT between BETWEEN HOSPIRA WORLDWIDE, INC. and THERAVANCE BIOPHARMA ANTIBIOTICS, INC. (Filed With SEC on November 9, 2016)

THIRD AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT between HOSPIRA WORLDWIDE, INC. and THERAVANCE BIOPHARMA IRELAND LIMITED (Filed With SEC on November 9, 2016)

FOURTH AMENDMENT TO TECHNOLOGY TRANSFER AND SUPPLY AGREEMENT between PFIZER, INC. and THERAVANCE BIOPHARMA IRELAND LIMITED (Filed With SEC on November 9, 2016)

THERAVANCE BIOPHARMA, INC. (a Cayman Islands exempted company) 3,850,000 Ordinary Shares UNDERWRITING AGREEMENT (Filed With SEC on November 2, 2016)

THERAVANCE BIOPHARMA, INC. (a Cayman Islands exempted company) $200,000,000 3.250% Convertible Senior Notes due 2023 UNDERWRITING AGREEMENT (Filed With SEC on November 2, 2016)

THERAVANCE BIOPHARMA, INC. as Issuer and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee Trustee Indenture Dated as of November 2, 2016 (Filed With SEC on November 2, 2016)

THERAVANCE BIOPHARMA, INC. 3.25% CONVERTIBLE SENIOR NOTES DUE 2023 FIRST SUPPLEMENTAL INDENTURE DATED AS OF NOVEMBER 2, 2016 WELLS FARGO BANK, NATIONAL ASSOCIATION AS TRUSTEE (Filed With SEC on November 2, 2016)

LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN THERAVANCE BIOPHARMA IRELAND LIMITED AND MILLENNIUM PHARMACEUTICALS, INC. DATED JUNE 8, 2016 (Filed With SEC on August 9, 2016)

AMENDMENT NO. 1 TO THE LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT (Filed With SEC on August 9, 2016)

THERAVANCE BIOPHARMA, INC. ORDINARY SHARE PURCHASE AGREEMENT March 14, 2016 (Filed With SEC on May 10, 2016)

THERAVANCE BIOPHARMA, INC. PERFORMANCE INCENTIVE PLAN PURPOSE (Filed With SEC on May 6, 2016)

THERAVANCE BIOPHARMA, INC. (a Cayman Islands exempted company) 4,765,000 Ordinary Shares UNDERWRITING AGREEMENT (Filed With SEC on May 2, 2016)

THERAVANCE BIOPHARMA, INC. 2013 EQUITY INCENTIVE PLAN NOTICE OF OPTION GRANT (Filed With SEC on March 11, 2016)

ACKNOWLEDGEMENT (Filed With SEC on March 11, 2016)

Theravance Biopharma, Inc. 2013 Equity Incentive Plan (the Plan) Irish Addendum (Filed With SEC on March 11, 2016)

Theravance Biopharma, Inc. 2014 New Employee Equity Incentive Plan (the Plan) Irish Addendum (Filed With SEC on March 11, 2016)

Theravance Biopharma, Inc. 2013 Employee Share Purchase Plan (the Plan) UK Addendum (Filed With SEC on March 11, 2016)

FIRST AMENDMENT TO RIGHTS AGREEMENT (Filed With SEC on November 10, 2015)

THERAVANCE BIOPHARMA, INC. ORDINARY SHARE PURCHASE AGREEMENT October 26, 2015 (Filed With SEC on October 26, 2015)

THERAVANCE BIOPHARMA, INC. ORDINARY SHARE PURCHASE AGREEMENT October 7, 2015 (Filed With SEC on October 13, 2015)

DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (Filed With SEC on April 24, 2015)

THERAVANCE BIOPHARMA, INC. ORDINARY SHARE PURCHASE AGREEMENT January 30, 2015 (Filed With SEC on April 24, 2015)

CONSULTING AGREEMENT (Filed With SEC on March 13, 2015)

EXHIBIT A Adjustments to Your Theravance Equity Awards in Connection with the Spin-Off (Filed With SEC on November 12, 2014)

Theravance Biopharma, Inc. 2013 Equity Incentive Plan (the Plan) UK ADDENDUM (Filed With SEC on August 14, 2014)

EXHIBIT A Adjustments to Your Theravance Equity Awards in Connection with the Spin-Off (Filed With SEC on August 14, 2014)

License Agreement (Filed With SEC on August 14, 2014)

CONSENT TO ASSIGNMENT (Filed With SEC on August 14, 2014)

SEPARATION AND DISTRIBUTION AGREEMENT by and between THERAVANCE, INC. and THERAVANCE BIOPHARMA, INC. Dated as of June 1, 2014 (Filed With SEC on June 3, 2014)

TRANSITION SERVICES AGREEMENT by and between THERAVANCE, INC. and THERAVANCE BIOPHARMA, INC. Dated as of June 2, 2014 (Filed With SEC on June 3, 2014)

TAX MATTERS AGREEMENT by and between THERAVANCE, INC. and THERAVANCE BIOPHARMA, INC. Dated as of June 2, 2014 (Filed With SEC on June 3, 2014)

EMPLOYEE MATTERS AGREEMENT by and between THERAVANCE, INC. and THERAVANCE BIOPHARMA, INC. Dated as of June 1, 2014 (Filed With SEC on June 3, 2014)

THERAVANCE RESPIRATORY COMPANY, LLC LIMITED LIABILITY COMPANY AGREEMENT May 31, 2014 (Filed With SEC on June 3, 2014)

Category

Industry

Companies

Contracts

Theravance Biopharma, Inc. Contracts & Agreements